Hyaluronidase consent has an operational problem that no amount of good intention solves: the moment you need it is the moment you cannot obtain it. Michelle Langston puts the question to injectors directly. "Patients should sign not only a consent for your filler but they should sign a consent for the hyaluronidase. Why is that important? Do you think I'm going to ask them for consent? No. I am going right into emergency mode, and they already know."
That is not a paperwork argument. It is a clinical one. Informed consent requires a patient who can understand what is being proposed, weigh the alternatives, and decide voluntarily. A patient sitting in your chair with a mottling upper lip, pain she cannot explain, and a clinician who has just gone quiet has none of those three. She cannot comprehend, because she is flooded. She cannot weigh alternatives, because the only real alternative is tissue loss. And she cannot decide voluntarily in any meaningful sense, because she is frightened and you are the only person in the room who knows what is happening.
So the consent has to already exist. Not as a clause buried in the filler consent, but as a second document, signed at intake, obtained during the good faith exam when the patient is calm, unhurried and capable of actually hearing what you are telling her.
Why a separate document rather than a clause
The obvious shortcut is to add a line to the filler consent — "I understand that in the event of a complication, hyaluronidase may be administered" — and consider the matter closed. It is a shortcut worth resisting, for four reasons.
It is a different treatment. Hyaluronidase is a different drug, with a different mechanism, a different risk profile, a different indication status and different consequences than the filler. Consent is treatment-specific for a reason. Bundling it into the filler consent treats it as an incidental feature of the filler rather than as an intervention the patient is agreeing to receive.
The second signature forces the conversation. This is the practical heart of it. A clause gets skimmed. A separate document with its own signature line makes someone stop and say something. That moment of friction is not a bug — it is the entire point of the exercise, because what you are really trying to install is not a signature but a memory.
It survives the emergency intact. Langston's protocol depends on a specific sentence being available to her mid-event: remember I talked to you about this. That sentence only works if the patient has a distinct recollection of a distinct conversation. If the discussion happened as clause fourteen of a four-page form, there is nothing to remember.
Its scope is broader than the emergency. This is the part most practices get wrong. Hyaluronidase is not only an emergency drug. It is used electively — for overcorrection, for nodules, for product migration, for asymmetry, for a result the patient no longer wants. Langston is explicit that her consent covers both: "in the event that I needed to dissolve it pretty urgently, or if we need to dissolve later, for as many reasons that we dissolve." A consent scoped only to vascular emergencies leaves you having a second consent conversation, months later, with a patient who is now unhappy. Scope it once, at intake, to cover every reason you would ever reach for the enzyme.
What the intake conversation actually sounds like
Langston's framing is short and it does a lot of work. Her version, in substance: we are putting needles in the face, we are injecting a product that may or may not enter a vessel, and so I am having you sign this second consent — in case I need to dissolve urgently, or in case we decide to dissolve later for any of the reasons we sometimes do.
Notice what that sentence establishes before anything has gone wrong.
It puts the word vessel in the room. The patient now has a mental model in which filler and blood vessels occupy the same space. That model is what makes your later action legible rather than alarming.
It sets the probability honestly — may or may not — without promising safety. It is not a reassurance, and it is not a warning designed to frighten someone out of treatment. It is a statement of how the anatomy works.
It establishes that you have a plan. The existence of a prepared document is itself the message. Patients read preparation as competence, correctly.
And it pre-authorises speed. When Langston moves into her protocol, she is not seeking permission. She is invoking a decision the patient already made, which is why she can spend her attention on the tissue rather than on a conversation.
Off-label use has to be on the form
Hyaluronidase products are approved as spreading agents — to increase the dispersion and absorption of other injected drugs and fluids. Using them to degrade hyaluronic acid dermal filler is off-label. Langston says so plainly: "Hyaluronidase is indicated for the filler use off label. We use it off label for dissolving things that we may not have anticipated, like overfilling."
Off-label use is lawful, common and appropriate. It is also something the patient is entitled to know about a drug you are proposing to give them, and it belongs in the document rather than in your memory of what you said. A consent that describes hyaluronidase as an approved treatment for filler complications is inaccurate on its face, and inaccuracy in a consent document is worse than silence.
The same principle governs how you describe the product. Hyaluronidase preparations differ in origin — recombinant human formulations versus animal-derived ones — and that difference matters for allergy history and for what you tell an emergency physician later. Name the product class you stock.
The patient's side of the agreement
A consent form is normally read as a one-way authorisation. Langston uses it as a two-way compact, and this is the most transferable idea in her protocol.
"They need to know: if we say it needs to be dissolved, then they need to come in and have it dissolved."
The scenario she is protecting against is the one she calls the most terrifying — a patient who sends a photograph of something that needs treatment and then does not come in. The photograph arrives, you recognise ischemia, and you have no patient. Every clinical tool you have is useless at a distance.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
Building that obligation into the intake conversation changes the later phone call. You are not persuading someone to come in. You are reminding them of something they already agreed to, which is a much shorter conversation at 7pm on a Friday. Put it in the document in plain language: if the treating clinician advises that the product should be dissolved, whether urgently or otherwise, the patient agrees to attend in person for assessment.
Where it sits in the workflow
Sequence matters as much as content. The hyaluronidase consent belongs in the same block as the good faith exam — after the history and examination, after you have decided the patient is a candidate, before photographs, and well before anything is drawn up.
It does not belong at the front desk with the intake paperwork. A form handed over with a clipboard and a pen becomes an administrative item, signed without reading, and the conversation you were trying to force never happens. It also does not belong at the end, after the patient is marked and anxious to get started — at that point it reads as a last-minute warning and will frighten people who were previously comfortable.
The workflow that works:
- Good faith exam — history, examination, candidacy, plan.
- Discussion of the treatment itself and its consent.
- Discussion of dissolution and the hyaluronidase consent, obtained by the clinician, not by staff.
- Photographs.
- Treatment.
There is one more operational requirement, and practices consistently overlook it: the signed consent has to be retrievable in seconds. If it lives in a filing cabinet in the back office, or in a chart that takes four clicks and a password reset to open, it is not functionally available during an emergency. Know where it is. Know who can produce it while you are injecting.
The hyaluronidase consent checklist
Every element below should appear in the document itself, not merely in the conversation. This list is the clinical content of the consent; the wording, jurisdictional requirements and any liability language are matters for your own counsel and your medical director.
- Identifies hyaluronidase by name and product class — including whether the preparation is recombinant human or animal-derived.
- States the off-label status for dissolution of hyaluronic acid filler, in plain language.
- Describes both indications: emergency use in suspected vascular compromise, and elective or deferred use for overcorrection, nodules, migration, asymmetry or an unwanted result.
- Explains the mechanism in one sentence the patient can repeat — an enzyme that breaks down hyaluronic acid, both the filler and the body's own.
- States that the patient's own tissue hyaluronic acid is also degraded, and that this is expected and temporary.
- States that the filler result will be reduced or lost, and that this may be partial, uneven, or more than intended.
- States that repeat dosing is usual, that a single treatment session may not resolve the problem, and that multiple sessions across multiple days may be required.
- Covers known and potential adverse reactions, including allergic and hypersensitivity reactions, and records the patient's relevant allergy history.
- Authorises administration without a further consent discussion in a suspected vascular emergency, and says explicitly why — that consent cannot meaningfully be obtained once treatment is urgent.
- Authorises emergency escalation: activation of emergency medical services, transfer to hospital, and release of treatment details to receiving clinicians.
- Records the patient's obligation to attend in person if dissolution is advised.
- Records the alternative — declining treatment — and what declining means in a vascular event.
- Is dated, versioned, signed by the patient and by the clinician who obtained it, with the version retained in the chart.
Print it. Put it in the pack. Review the version annually and whenever you change product.
This is a clinical operations argument, not legal advice
Empire Medical Training does not give legal advice, and nothing here is a substitute for it. Consent requirements vary by state, by licensure, by scope of practice and by the terms of your medical director agreement. The argument in this article is a clinical and operational one: that the sequence in which consent is obtained determines whether it exists when it is needed. Take the structure to your own counsel and have the document drafted or reviewed properly.
The same discipline applies to every consent in the practice, and the principles carry across product classes — our guide to what belongs in a neurotoxin consent form covers the general anatomy of a good aesthetic consent document. For the conversation patients themselves are searching for when they want to understand dissolution, our overview of filler dissolving is the page to hand them after the discussion, and our summary of common lip filler reactions covers the expected-response material that patients confuse with complications.
The underlying principle
Langston returns to the same idea across every part of her protocol, and the consent is simply its administrative form: "The most important thing is to prepare for the emergency when you don't have the emergency."
Consent obtained under duress is not consent, and the emergency is by definition duress. So the work moves upstream — into the good faith exam, into a document with its own signature line, into a sixty-second conversation with a calm patient who will remember it. When the tissue changes, you inject. You do not negotiate.
Empire's Complete Dermal Filler Training and Complete Facial Aesthetic Training cover complication preparedness alongside injection technique, because the two are the same skill set viewed from different ends.
The protocols described here reflect Michelle Langston's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training or for legal advice.
Frequently Asked Questions
Why can't I just add hyaluronidase to my existing filler consent form?
Because a clause gets skimmed and a separate signature forces a conversation. Michelle Langston's protocol depends on being able to say "remember I talked to you about this" mid-emergency, and that only works if the patient recalls a distinct discussion. A separate document also lets you scope the consent to elective dissolution, which a filler consent does not cover.
Is using hyaluronidase to dissolve filler off-label?
Yes. Hyaluronidase products are approved as spreading agents to aid dispersion and absorption of other injected substances. Using them to degrade hyaluronic acid dermal filler is off-label — lawful and standard practice, but off-label. That status belongs in the consent document in plain language, not only in your recollection of the conversation.
When in the visit should the hyaluronidase consent be obtained?
During the good faith exam, after you have assessed candidacy and before photographs or drawing up product. It should be obtained by the clinician rather than handed over at the front desk, because the purpose is the conversation rather than the signature. Obtaining it at the end, after the patient is marked, reads as a last-minute warning.
What if a patient refuses to sign the hyaluronidase consent?
Treat that as a screening result. A patient unwilling to authorise the only effective treatment for the most serious complication of the procedure is not a candidate for that procedure. The refusal is worth understanding — it is usually a comprehension problem rather than a real objection — but proceeding without it leaves you with no lawful, timely option in an emergency.
Does the consent need to cover dissolving filler someone else injected?
It should. Patients frequently present with product placed elsewhere, and the elective indications — migration, nodules, overcorrection — are exactly where that comes up. Scope the document to the enzyme and its indications rather than to one treatment episode, and record what is known about the prior product, including that it may be unknown.
Disclaimer
This article reflects the clinical opinions and experience of Michelle Langston, APRN, MSN, FNP-BC, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
